Reliability and delay analysis of slotted anycast multi-hop wireless networks targeting dense traffic iot applications

Studies on IEEE 802.15.4 MAC in the current literature for anycast multi-hop networks do not capture a node's behaviour accurately. Due to the inaccurate modeling of state-wise behaviour of a node, the optimization of network parameters has not been efficient so far. In this work, we include the state-wise behaviour of a relay node into a 3D Markov model to more accurately investigate the protocol performance. Performance analysis of the proposed analytical model is evaluated for different variants of active state length, packet length and wake up rates considering reliability and delay as key performance metrics. Performance analysis shows that the model captures the behaviour of relay nodes most accurately

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

High-resolution spectroscopy and spectropolarimetry of selected delta Sct pulsating variables

The combination of photometry, spectroscopy and spectropolarimetry of the chemically peculiar stars often aims to study the complex physical phenomena such as stellar pulsation, chemical inhomogeneity, magnetic field and their interplay with stellar atmosphere and circumstellar environment. The prime objective of this study is to determine the atmospheric parameters of a set of Am stars to understand their evolutionary status. Atmospheric abundances and basic parameters are determined using full spectrum fitting technique by comparing the high-resolution spectra to the synthetic spectra. To know the evolutionary status, we derive the effective temperature and luminosity from different methods and compare them with the literature. The location of these stars in the Hertzsprung-Russell diagram demonstrates that all the sample stars are evolved from the zero-age main sequence towards terminal-age main sequence and occupy the region of delta Sct instability strip. The abundance analysis shows that the light elements e.g. Ca and Sc are underabundant while iron peak elements such as Ba, Ce, etc. are overabundant and these chemical properties are typical for Am stars. The results obtained from the spectropolarimetric analysis of our studied stars show that the longitudinal magnetic field is negligible in all of them, which further support to their Am class of peculiarity

Multifunctional Cytokine Expression by Human Coronary Endothelium and Regulation by Monokines and Glucocorticoids

Human endothelium is capable of expressing a variety of molecules, including cytokines and growth factors, critical to inflammation. This aspect of coronary endothelium has not been studied in detail. In this study, we report, for the first time, expression of multifunctional cytokines by human coronary artery endothelial cells (HCAEC) and their regulation by inflammatory cytokines and glucocorticoids. We also compared expression of cytokine transcripts in two additional cell lines derived from pulmonary artery (HPAEC) and umbilical vein (HUVEC) endothelium. HCAEC expressed transcripts for interleukin 5 (IL-5), IL-6, IL-8, and monocyte chemotactic protein-1 (MCP-1) constitutively. Induction of IL-1α, IL-6, granulocyte- macrophage colony-stimulating factor (GM-CSF), and MCP-1 was seen following treatment with TNFα. We found no expression of IL-1RA, IL-2, IL-4, IL-13, TNF-α, or IFN-γ in HCAEC. IL-1β and TNF-α synergistically induced IL-6 and GM-CSF and additively induced IL-8 and MCP-1 production, while IL-2, IL- 10, IFN-α, and IFN-γ had little or no additional effects. Interestingly, no IL-1α or IL-5 protein product was found even after maximal stimulation of HCAEC. No significant differences were seen in the profile of cytokine genes expressed by HCAEC, HPAEC, or HUVEC. Glucocorticoids inhibited IL-8 production from all three cell lines. This study demonstrates that human coronary endothelial cells are capable of expressing a wide variety of multifunctional cytokines which may be of relevance to vascular inflammation

High-resolution spectroscopy and spectropolarimetry of selected delta Sct pulsating variables

The combination of photometry, spectroscopy and spectropolarimetry of the chemically peculiar stars often aims to study the complex physical phenomena such as stellar pulsation, chemical inhomogeneity, magnetic field and their interplay with stellar atmosphere and circumstellar environment. The prime objective of this study is to determine the atmospheric parameters of a set of Am stars to understand their evolutionary status. Atmospheric abundances and basic parameters are determined using full spectrum fitting technique by comparing the high-resolution spectra to the synthetic spectra. To know the evolutionary status, we derive the effective temperature and luminosity from different methods and compare them with the literature. The location of these stars in the Hertzsprung-Russell diagram demonstrates that all the sample stars are evolved from the zero-age main sequence towards terminal-age main sequence and occupy the region of delta Sct instability strip. The abundance analysis shows that the light elements e.g. Ca and Sc are underabundant while iron peak elements such as Ba, Ce, etc. are overabundant and these chemical properties are typical for Am stars. The results obtained from the spectropolarimetric analysis of our studied stars show that the longitudinal magnetic field is negligible in all of them, which further support to their Am class of peculiarity